{
    "info": {
        "nct_id": "NCT03822871",
        "official_title": "A Phase 1 Trial for Evaluation of Safety and 177Lu Radiation Dosimetry of CTT1403: A Peptidomimetic Inhibitor of Prostate Specific Membrane Antigen, in Metastatic Castration Resistant Prostate Cancer (mCRPC)",
        "inclusion_criteria": "* Patients must have histologically confirmed prostate adenocarcinoma that is metastatic and castration resistant (mCRPC).\n* At least 3 metastatic foci avid for PSMA-specific PET agent (CTT1057) uptake on Screening PSMA PET.\n* Has received docetaxol, ineligible for docetaxol, or refused docetaxol for the treatment of prostate cancer.\n* Has progression by the PCWG3 criteria during or after treatment with either abiraterone or enzalutamide\n* Male Age ≥ 18 years.\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see Appendix 2).\n* Demonstrate adequate organ function\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has received previous treatment with radium-223 or another radiopharmaceutical within 3 months prior to first dose of CTT1403.\n* Has received prior systemic anti-cancer therapy (excluding radiopharmaceutical) within 14 days, or 5 half-lives, whichever is shorter, prior to first dose of CTT1403.\n* Has received external-beam radiation within 14 days prior to first dose of CTT1403.\n* Has received cabazitaxel for the treatment of mCRPC.\n* Has received previous treatment with a therapeutic targeting PSMA.\n* Has an additional active malignancy requiring therapy that may confound the assessment of the study endpoints.\n* Has clinically significant cardiovascular disease\n* Has a history of untreated brain metastases\n* Has evidence of diffuse bone marrow involvement by prostate cancer in the judgment of study investigator.\n* Clinically significant urinary obstruction or moderate/severe hydronephrosis on baseline imaging.\n* Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before CTT1403 administration.\n* Has known positive status for chronic hepatitis B or hepatitis C\n* Known or suspected myelodysplastic syndrome.\n* Has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Demonstrate adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Demonstrate adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has progression by the PCWG3 criteria during or after treatment with either abiraterone or enzalutamide",
            "criterions": [
                {
                    "exact_snippets": "Has progression by the PCWG3 criteria",
                    "criterion": "disease progression by PCWG3 criteria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "during or after treatment with either abiraterone or enzalutamide",
                    "criterion": "treatment with abiraterone or enzalutamide",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "during",
                                "after"
                            ]
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "abiraterone",
                                "enzalutamide"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see Appendix 2).",
            "criterions": [
                {
                    "exact_snippets": "Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 3 metastatic foci avid for PSMA-specific PET agent (CTT1057) uptake on Screening PSMA PET.",
            "criterions": [
                {
                    "exact_snippets": "At least 3 metastatic foci avid for PSMA-specific PET agent (CTT1057) uptake on Screening PSMA PET",
                    "criterion": "metastatic foci with PSMA-specific PET agent uptake",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "foci"
                            }
                        },
                        {
                            "requirement_type": "avidity for PSMA-specific PET agent (CTT1057) uptake",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "Screening PSMA PET"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received docetaxol, ineligible for docetaxol, or refused docetaxol for the treatment of prostate cancer.",
            "criterions": [
                {
                    "exact_snippets": "Has received docetaxol",
                    "criterion": "docetaxel treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of administration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ineligible for docetaxol",
                    "criterion": "docetaxel eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "refused docetaxol",
                    "criterion": "docetaxel treatment",
                    "requirements": [
                        {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male Age ≥ 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Male",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have histologically confirmed prostate adenocarcinoma that is metastatic and castration resistant (mCRPC).",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed prostate adenocarcinoma",
                    "criterion": "prostate adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "castration resistant (mCRPC)",
                    "criterion": "castration resistance",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "resistant"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Clinically significant urinary obstruction or moderate/severe hydronephrosis on baseline imaging.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant urinary obstruction",
                    "criterion": "urinary obstruction",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "moderate/severe hydronephrosis on baseline imaging",
                    "criterion": "hydronephrosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "on baseline imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has evidence of diffuse bone marrow involvement by prostate cancer in the judgment of study investigator.",
            "criterions": [
                {
                    "exact_snippets": "evidence of diffuse bone marrow involvement by prostate cancer",
                    "criterion": "diffuse bone marrow involvement by prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the judgment of study investigator",
                    "criterion": "study investigator judgment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "judged by study investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received external-beam radiation within 14 days prior to first dose of CTT1403.",
            "criterions": [
                {
                    "exact_snippets": "Has received external-beam radiation within 14 days prior to first dose of CTT1403.",
                    "criterion": "external-beam radiation",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose of CTT1403"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known positive status for chronic hepatitis B or hepatitis C",
            "criterions": [
                {
                    "exact_snippets": "known positive status for chronic hepatitis B",
                    "criterion": "chronic hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "infection status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known positive status for ... hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "infection status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior systemic anti-cancer therapy (excluding radiopharmaceutical) within 14 days, or 5 half-lives, whichever is shorter, prior to first dose of CTT1403.",
            "criterions": [
                {
                    "exact_snippets": "Has received prior systemic anti-cancer therapy (excluding radiopharmaceutical) within 14 days, or 5 half-lives, whichever is shorter, prior to first dose of CTT1403.",
                    "criterion": "prior systemic anti-cancer therapy (excluding radiopharmaceutical)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has clinically significant cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received cabazitaxel for the treatment of mCRPC.",
            "criterions": [
                {
                    "exact_snippets": "Has received cabazitaxel for the treatment of mCRPC.",
                    "criterion": "cabazitaxel treatment for mCRPC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected myelodysplastic syndrome.",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected myelodysplastic syndrome",
                    "criterion": "myelodysplastic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis or suspicion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received previous treatment with radium-223 or another radiopharmaceutical within 3 months prior to first dose of CTT1403.",
            "criterions": [
                {
                    "exact_snippets": "Has received previous treatment with radium-223 or another radiopharmaceutical within 3 months prior to first dose of CTT1403.",
                    "criterion": "previous treatment with radium-223 or another radiopharmaceutical",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to first dose of CTT1403"
                            }
                        },
                        {
                            "requirement_type": "treatment_received",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.",
            "criterions": [
                {
                    "exact_snippets": "any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "risk for toxicities (as judged by Investigator)",
                            "expected_value": "unacceptably high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before CTT1403 administration.",
            "criterions": [
                {
                    "exact_snippets": "Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) ... within 14 days before CTT1403 administration.",
                    "criterion": "systemic corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily prednisone equivalents"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before CTT1403 administration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a condition requiring systemic treatment with ... other immunosuppressive medications within 14 days before CTT1403 administration.",
                    "criterion": "systemic immunosuppressive medication treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before CTT1403 administration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received previous treatment with a therapeutic targeting PSMA.",
            "criterions": [
                {
                    "exact_snippets": "Has received previous treatment with a therapeutic targeting PSMA",
                    "criterion": "previous treatment with a therapeutic targeting PSMA",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an additional active malignancy requiring therapy that may confound the assessment of the study endpoints.",
            "criterions": [
                {
                    "exact_snippets": "Has an additional active malignancy requiring therapy",
                    "criterion": "additional active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requiring therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of untreated brain metastases",
            "criterions": [
                {
                    "exact_snippets": "history of untreated brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}